Feb 17 (Reuters) - Memphasys Ltd (MEM)
- Provides following details and a summary of dispute resolution process it has commenced
- Prime Biologics Pte Ltd ("Prime") and Memphasys Ltd have agreed by mutual consent in legal proceedings in Nsw Supreme Court
- Now filed an application for arbitration in Singapore to hear and resolve dispute between Memphasys, Prime Biologics and Manukan
- Arbitration will primarily deal with s$4.8 million debt associated with fit-out of rental facility that prime is using in singapore
- Memphasys remains optimistic that a positive outcome from arbitration process will be achieved
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.926M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9869614 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5231352 | 3 |
View Market Depth
| Last trade - 11.47am 18/09/2025 (20 minute delay) ? |
| MEM (ASX) Chart |
Day chart unavailable